- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (Nasdaq: ARWR)announced today that Dr. Mauro Ferrari, Chair of Arrowhead's Scientific Advisory Board, has been named the President and CEO of The Methodist Hospital Research Institute.
The Institute, based in Houston, Texas, was formed in 2004 to rapidly and efficiently translate discoveries made in the laboratory and the clinic into new diagnostics, therapies, and treatments. Important advances in biomedical sciences and healthcare are made by collaborative, interdisciplinary teams of individuals with diverse scientific backgrounds and training. TMHRI was created to provide the infrastructure and support for these endeavors, and to house the technology and resources needed to make innovative breakthroughs in important areas of human disease.
Dr. Ferrari is the also co-founder and a member of the Board of Directors of Leonardo Biosystems, a minority investment of Arrowhead Research.
"We congratulate Mauro on this prestigious appointment," said Dr. Christopher Anzalone, Arrowhead's CEO. "At Arrowhead, we count on Mauro's vision and passion for bridging the gap between 21st century science and real-life medical problems. Mauro's visionary leadership will surely be of great benefit in implementing TMHRI's mission."
Dr. Ferrari is the president of the Alliance for NanoHealth, and he serves as professor of experimental therapeutics at The University of Texas M.D. Anderson Cancer Center, and professor of bioengineering at Rice University. He is a fellow of the American Academy for the Advancement of Science (AAAS), American Institute for Medical and Biological Engineering, and the American Society of Mechanical Engineers. Most recently, Dr. Ferrari served as chair of the Department of Nanomedicine and Biomedical Engineering at the University of Texas Health Science Center at Houston. Prior to joining the faculty of the University of Texas, Dr. Ferrari was a tenured professor at both Ohio State University and the University of California at Berkeley with primary research interests in biomedical engineering.
He has over 200 published works and has been invited to speak on biomedical nanotechnology and other topics worldwide.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.
For more information, please click here
The Piacente Group
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information